Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

ClinicalTrials.gov ID: NCT00144339

Public ClinicalTrials.gov record NCT00144339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Study identification

NCT ID
NCT00144339
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
5,993 participants

Conditions and interventions

Interventions

  • tiotropium Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2002
Primary completion
Jan 31, 2008
Completion
Not listed
Last update posted
May 19, 2014

Started 2002

United States locations

U.S. sites
95
U.S. states
34
U.S. cities
85
Facility City State ZIP Site status
205.235.3779 Boehringer Ingelheim Investigational Site Anniston Alabama
205.235.3785 Boehringer Ingelheim Investigational Site Birmingham Alabama
205.235.3804 Boehringer Ingelheim Investigational Site Jasper Alabama
205.235.3795 Boehringer Ingelheim Investigational Site Mobile Alabama
205.235.3759 Boehringer Ingelheim Investigational Site Phoenix Arizona
205.235.3770 Boehringer Ingelheim Investigational Site Carmichael California
205.235.3778 Boehringer Ingelheim Investigational Site Escondito California
205.235.3810 Boehringer Ingelheim Investigational Site Lakewood California
205.235.3758 Boehringer Ingelheim Investigational Site Long Beach California
205.235.3812 Boehringer Ingelheim Investigational Site Long Beach California
205.235.3773 Boehringer Ingelheim Investigational Site Los Angeles California
205.235.3800 Boehringer Ingelheim Investigational Site Los Angeles California
205.235.3802 Boehringer Ingelheim Investigational Site Los Angeles California
205.235.3786 Pulmonary and Critical Care Medicine Orange California
205.235.3811 Boehringer Ingelheim Investigational Site Palo Alto California
205.235.3741 Boehringer Ingelheim Investigational Site Rancho Mirage California
205.235.3717 Boehringer Ingelheim Investigational Site San Diego California
205.235.3781 Boehringer Ingelheim Investigational Site San Diego California
205.235.3784 Boehringer Ingelheim Investigational Site San Diego California
205.235.3760 Boehringer Ingelheim Investigational Site Sepulveda California
205.235.3711 Boehringer Ingelheim Investigational Site Stockton California
205.235.3764 Boehringer Ingelheim Investigational Site Denver Colorado
205.235.3783 Boehringer Ingelheim Investigational Site Wheat Ridge Colorado
205.235.3727 Boehringer Ingelheim Investigational Site Hartford Connecticut
205.235.3808 Boehringer Ingelheim Investigational Site Hartford Connecticut
205.235.3793 Boehringer Ingelheim Investigational Site Norwalk Connecticut
205.235.3815 Boehringer Ingelheim Investigational Site West Haven Connecticut
205.235.3706 Boehringer Ingelheim Investigational Site Bay Pines Florida
205.235.3762 Boehringer Ingelheim Investigational Site Brandon Florida
205.235.3707 Boehringer Ingelheim Investigational Site Largo Florida
205.235.3703 Boehringer Ingelheim Investigational Site Melbourne Florida
205.235.3775 Boehringer Ingelheim Investigational Site Panama City Florida
205.235.3743 Boehringer Ingelheim Investigational Site Sarasota Florida
205.235.3756 Boehringer Ingelheim Investigational Site Tampa Florida
205.235.3739 Boehringer Ingelheim Investigational Site West Palm Beach Florida
205.235.3719 Boehringer Ingelheim Investigational Site Atlanta Georgia
205.235.3790 Boehringer Ingelheim Investigational Site Atlanta Georgia
205.235.3716 Boehringer Ingelheim Investigational Site Augusta Georgia
205.235.3794 Boehringer Ingelheim Investigational Site Stockbridge Georgia
205.235.3724 Boehringer Ingelheim Investigational Site Coeur d'Alene Idaho
205.235.3713 Boehringer Ingelheim Investigational Site Normal Illinois
205.235.3768 Boehringer Ingelheim Investigational Site Indianapolis Indiana
205.235.3749 Boehringer Ingelheim Investigational Site Dubuque Iowa
205.235.3757 Boehringer Ingelheim Investigational Site Olathe Kansas
205.235.3729 Boehringer Ingelheim Investigational Site Lexington Kentucky
205.235.3737 Boehringer Ingelheim Investigational Site Metairie Louisiana
205.235.3788 Boehringer Ingelheim Investigational Site Shreveport Louisiana
205.235.3750 Boehringer Ingelheim Investigational Site Bidderford Maine
205.235.3806 Boehringer Ingelheim Investigational Site Baltimore Maryland
205.235.3721 Boehringer Ingelheim Investigational Site Boston Massachusetts
205.235.3726 354 Birnie Ave Springfield Massachusetts
205.235.3813 Boehringer Ingelheim Investigational Site Ann Arbor Michigan
205.235.3732 Boehringer Ingelheim Investigational Site Detroit Michigan
205.235.3809 Boehringer Ingelheim Investigational Site Livonia Michigan
205.235.3751 Boehringer Ingelheim Investigational Site Minneapolis Minnesota
205.235.3754 Boehringer Ingelheim Investigational Site Minneapolis Minnesota
205.235.3789 Boehringer Ingelheim Investigational Site Rochester Minnesota
205.235.3734 Boehringer Ingelheim Investigational Site Chesterfield Missouri
205.235.3814 Boehringer Ingelheim Investigational Site Kansas City Missouri
205.235.3747 Boehringer Ingelheim Investigational Site St Louis Missouri
205.235.3763 Boehringer Ingelheim Investigational Site Lebanon New Hampshire
205.235.3797 Boehringer Ingelheim Investigational Site Cherry Hill New Jersey
205.235.3799 Boehringer Ingelheim Investigational Site Summit New Jersey
205.235.3796 Boehringer Ingelheim Investigational Site Albany New York
205.235.3807 Boehringer Ingelheim Investigational Site Bay Shore New York
205.235.3765 Boehringer Ingelheim Investigational Site Larchmont New York
205.235.3748 Boehringer Ingelheim Investigational Site Mineola New York
205.235.3818 Boehringer Ingelheim Investigational Site New York New York
205.235.3722 Boehringer Ingelheim Investigational Site Rochester New York
205.235.3816 Boehringer Ingelheim Investigational Site The Bronx New York
205.235.3730 Boehringer Ingelheim Investigational Site Burlington North Carolina
205.235.3731 Boehringer Ingelheim Investigational Site Chapel Hill North Carolina
205.235.3736 Boehringer Ingelheim Investigational Site Durham North Carolina
205.235.3745 Boehringer Ingelheim Investigational Site Elizabath City North Carolina
205.235.3712 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina
205.235.3723 Boehringer Ingelheim Investigational Site Cincinnati Ohio
205.235.3701 Boehringer Ingelheim Investigational Site Cleveland Ohio
205.235.3791 Boehringer Ingelheim Investigational Site Tulsa Oklahoma
205.235.3820 Boehringer Ingelheim Investigational Site Portland Oregon
205.235.3725 Boehringer Ingelheim Investigational Site Hershey Pennsylvania
205.235.3817 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
205.235.3715 Boehringer Ingelheim Investigational Site Providence Rhode Island
205.235.3803 Boehringer Ingelheim Investigational Site El Paso Texas
205.235.3742 Boehringer Ingelheim Investigational Site Houston Texas
205.235.3787 Boehringer Ingelheim Investigational Site Houston Texas
205.235.3704 Boehringer Ingelheim Investigational Site San Antonio Texas
205.235.3752 Boehringer Ingelheim Investigational Site Salt Lake City Utah
205.235.3744 Boehringer Ingelheim Investigational Site Danville Virginia
205.235.3782 Boehringer Ingelheim Investigational Site Fredericksburg Virginia
205.235.3771 Boehringer Ingelheim Investigational Site Lynchburg Virginia
205.235.3738 Boehringer Ingelheim Investigational Site Richmond Virginia
205.235.3792 Boehringer Ingelheim Investigational Site Richmond Virginia
205.235.3761 Boehringer Ingelheim Investigational Site Salem Virginia
205.235.3718 Boehringer Ingelheim Investigational Site Spokane Washington
205.235.3780 Boehringer Ingelheim Investigational Site La Crosse Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 395 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00144339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 19, 2014 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00144339 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →